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Background: Ovarian cancer is characterized by high rates of metastasis and therapeutic resistance. Many
chemotherapeutic agents rely on the induction of oxidative stress to cause cancer cell death, thus targeting redox
regulation is a promising strategy to overcome drug resistance.
Methods: We have used a tetracycline-inducible Ets-1 overexpression model derived from 2008 ovarian cancer cells
in the present study. To examine the role of Ets-1 in glutathione regulation we have measured intracellular reactive
oxygen species and glutathione levels, as well as glutathione peroxidase enzyme activity. Glutathione synthesis was
limited using transsulfuration or Sxc
- pathway blocking agents, and glutamate release was measured to confirm Sxc
-
blockade. Cell viability following drug treatment was assessed via crystal violet assay. Oxidative stress was induced
through glucose oxidase treatment, which produces hydrogen peroxide by glucose oxidation. The protein expressions
of redox-related factors were measured through western blotting.
Results: Overexpression of Ets-1 was associated with decreased intracellular ROS, concomitantly with increased
intracellular GSH, GPX antioxidant activity, and Sxc
- transporter activity. Under basal conditions, inhibition of the
transsulfuration pathway resulted in decreased GSH levels and GPX activity in all cell lines, whereas inhibition
of Sxc
- by sulfasalazine decreased GPX activity in Ets-1-expressing cells only. However, under oxidative stress
the intracellular GSH levels decreased significantly in correlation with increased Ets-1 expression following
sulfasalazine treatment.
Conclusions: In this study we have identified a role for proto-oncogene Ets-1 in the regulation of intracellular
glutathione levels, and examined the effects of the anti-inflammatory drug sulfasalazine on glutathione depletion
using an ovarian cancer cell model. The findings from this study show that Ets-1 mediates enhanced Sxc
- activity
to increase glutathione levels under oxidative stress, suggesting that Ets-1 could be a promising putative target
to enhance conventional therapeutic strategies.
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Ovarian cancer, much like several types of human cancer,
remains extremely challenging to treat in advanced
stages despite prolific therapeutic advances. Patients
with ovarian cancer generally have a poor prognosis, as
most women are not diagnosed until the disease has
reached advanced stages. Surgical intervention is the
most successful treatment, however, due to the close
proximity of other peritoneal structures to the ovary,
recurrence of the disease within nearby organs is very* Correspondence: singhg@mcmaster.ca
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distribution, and reproduction in any mediumcommon [1]. As recurrent ovarian cancer remains a
largely incurable state of disease, it is vitally important
to examine the characteristic differences between early
and late stage ovarian cancers, and mechanisms of
therapeutic resistance. Cisplatin and other platinum
drugs are the most common first round chemotherapeutic
agents used to treat ovarian cancer, where most patients
who receive treatment experience platinum-sensitive
recurrence, typically followed by the eventual development
of platinum drug resistance [2].
The specific mechanisms involved in the development
of therapeutic resistance are not fully understood,
however it is well-recognized to be a multi-factorialCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,








































































































Figure 1 Ets-1 decreases intracellular ROS, while increasing
intracellular GSH and GPX activity. A) Basal intracellular ROS levels
were measured in 2008, 2008-Ets1 (Ets-1), and tetracycline-induced
2008-Ets1 (Ets-1 + Tet) cells using CM2-H2DCFDA. There is a trend for
decreased ROS levels in correlation with increased Ets-1 expression
(n = 3). B) Total intracellular amounts of GSH were measured using
an enzymatic recycling method as described by Rahman et al. (12).
Metabolite extracts from 2008, Ets-1 and induced Ets-1 cells con-
tained increased GSH levels concomitantly with increased Ets-1
expression (n = 4). C) Glutathione peroxidase activity also displayed a
trend towards increased activity in association with higher levels of
Ets-1 expression (n = 4).
Verschoor and Singh Molecular Cancer 2013, 12:138 Page 2 of 11
http://www.molecular-cancer.com/content/12/1/138process involving alterations in drug metabolism and
transport, DNA damage signaling and repair, apoptosis
and survival signaling, as well as off-target changes
that counteract the lethal effects of the chemotherapy
[2]. Recently, cancer stem cells have been revealed as a key
cell type involved in the recurrence and drug resistance
of ovarian cancer [2-6]. Due to the heterogeneous nature
of ovarian cancer tumors, it is thought that primary
tumours are composed of drug sensitive cells, resistant
cells, and cancer initiating stem cells. In this theory,
the bulk of primary tumours are composed of sensitive
cells that succumb to initial chemotherapy treatment,
however the population of cancer stem cells that are
drug resistant repopulate the tumour resulting in drug
resistance upon recurrence.
Importantly, drug resistance in ovarian cancer is often
characterized by the acquisition of genetic modifications
in key signaling pathways such as p53 and Akt [7]. Our
research group has previously established that the
transcription factor v-ets erythroblastosis virus E26
oncogene homolog 1 (Ets-1) is associated with chemo-
therapeutic resistance in ovarian cancer cells, whereby
increased expression of Ets-1 results in decreased
sensitivity to cisplatin [8]. More recently, we have
established that Ets-1 regulates energy metabolism in
ovarian cancer cells by enhancing glycolytic dependence,
and also extended these findings to a breast cancer
model [9,10]. The increased glycolytic utilization observed
was paired with increases in the expression of several
pentose phosphate pathway genes. This pathway is one
of the major sources of NADPH that is required for
glutathione reduction, which is an important factor in
therapeutic resistance. Therefore, because Ets-1 overex-
pression leads to increased glycolytic flux, it is possible
that Ets-1 is also involved in the regulation of cellular
redox state since these processes are intrinsically linked.
The balance between cell death and proliferation is
tightly controlled in healthy cells, whereas in cancer
cells this equilibrium is shifted towards a proliferative
state with enhanced survival. Imbalances in cellular
redox state are frequently observed in cancer cells, and
contribute significantly to cancer progression and apop-
totic resistance. Reduced glutathione (GSH) is the most
abundant non-protein thiol in mammalian cells, and
tightly regulates redox state through its antioxidant and
reducing activities. Additionally, GSH is involved in the
control of cell cycle regulation, proliferation, apoptosis,
and therapeutic resistance in cancer cells [11-14]. Many
chemotherapeutic agents and radiation treatments depend
on the alteration of redox state through the induction
of oxidative stress via reactive oxygen species (ROS)
generation to kill cancer cells. Changes in GSH levels
affect mitochondrial pore permeability, where depletion
of GSH leads to the release of cytochrome c and cell
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cancer therapy that could ameliorate the success of
conventional therapies [15]. Interestingly, glutathione
levels are higher in ovarian tumours than in healthy
ovarian tissue, and increase in patients who are non-
responsive to therapeutic intervention [16,17].
In this study, we reveal that Ets-1 elevates cellular
glutathione levels in ovarian cancer cells, which could
account for the therapeutic resistance associated with
this transcription factor. We have shown that ovarian
cancer cells that overexpress Ets-1 display decreased
intracellular ROS, with increased intracellular GSH and
glutathione peroxidase (GPX) antioxidant activity. The
availability of intracellular cysteine is rate-limiting for
GSH synthesis, and is determined by the activities of the
transsulfuration pathway and the membrane antiporter
System xc
- (Sxc
-), which imports cystine in exchange for
glutamate release. We have used inhibitors of each of
these systems to determine whether Ets-1 plays a role in
the regulation of either pathway, thus explaining the
changes in GSH that we have observed. Our results
show that Ets-1 mediates enhanced Sxc
- activity to in-
crease glutathione recycling in ovarian cancer cells, and





















































































Figure 2 Ets-1 increases System xc
- expression and activity. A) The pro
transsulfuration pathway enzyme CBS were compared in 2008 and induced
not different, xCT protein levels were increased in response to Ets-1 overex
fluorescence in 2008 and 2008-Ets1 cells under basal or SAS-treated condit
culture medium, and SAS was an effective inhibitor of glutamate release (n
SAS treatment, which was found to decrease viability in all cell lines (n=3).our knowledge, this is the first study to report that Ets-1
regulates glutathione levels in cancer cells, suggesting
that Ets-1 could be a promising putative target to
increase the effectiveness of therapeutic strategies
dependent on GSH depletion.
Results
Ets-1 decreases intracellular ROS, while increasing
intracellular GSH and GPX activity
To examine the role of Ets-1 in the regulation of cellular
antioxidant capacity, we measured intracellular ROS
levels, total cellular GSH, and GPX enzyme activity.
Intracellular ROS was measured using CM2-H2DCFDA
in 2008, 2008-Ets1, and induced 2008-Ets1 cells
(Figure 1A). The amount of ROS present in induced
2008-Ets1 cells (1264.4 AFU) was significantly less than
their parental 2008 cells (1885.5 AFU), while non-
induced 2008-Ets1 cells were not significantly different.
Quantitative total GSH was measured via colourimetric
assay under basal conditions, and both 2008-Ets1 and
induced 2008-Ets1 cells showed increased amounts of
total GSH relative to 2008 cells (11.11- and 22.14-fold
respectively) (Figure 1B). GPX enzyme activity was
























tein expression of the catalytic subunit of Sxc
- , xCT, and the
2008-Ets1 cells via Western Blot. Though the expression of CBS was
pression (n = 3). B) Glutamate release was measured by AMPLEX red®
ions. Cells that overexpress Ets-1 release more glutamate into the
= 3). C) Cell viability was measured via Crystal Violet assay following
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GPX activity rate (1.96-fold) than 2008 cells (Figure 1C).
Ets-1 increases System xc
- expression and activity
The protein expression of xCT, the subunit of Sxc
-
responsible for transporter activity of the antiporter, and
of CBS, which catalyzes the first step of the transsulfura-
tion pathway, were examined in 2008 and induced 2008-
Ets1 cells (Figure 2A). The expression of xCT was found
to be 4.6-fold higher in induced 2008-Ets1 cells com-
pared to parental 2008 cells via densitometry analysis.
No significant difference in the expression of CBS was
found between 2008 and induced 2008-Ets1 cells. The
amount of glutamate released into the culture medium
was measured, and used to test the effectiveness of
SAS in blocking Sxc
- transporter activity. Both non-
induced and induced 2008-Ets1 cells released more
glutamate into the culture environment than parental
2008 cells (2.04-fold and 2.53-fold respectively)
(Figure 2B). Treatment with SAS, an inhibitor of Sxc
- ,
resulted in a significant reduction of extracellular glu-
tamate for all cell lines. Additionally, SAS treatmentA C
B
Figure 3 The transsulfuration pathway is a major GSH source in norm
ovarian cancer cells were treated with PPG or SAS for 24 hrs, and the redo
cantly decreased in response to PPG treatment in all cell lines, while SAS d
enzyme activity of GPX was significantly decreased by PPG-mediated block
creased GPX activity only in Ets-1 overexpression cell lines (n = 3). C) The p
via Western blot, including Ets-1, HIF-1α, xCT, GPX-1, and GPX-2, with actinsignificantly decreased cell viability in all cell types of our
model system (Figure 2C), a finding that is in accordance
with previously published work by Lo et al. [18].
The transsulfuration pathway is a major GSH source in
ovarian cancer cells
To identify the role of Ets-1 in regulating either of the
transsulfuration or Sxc
- sources of GSH, we have used spe-
cific inhibitors of both pathways. Propargylglycine (PPG) ir-
reversibly inhibits the cystathionine γ-lyase enzyme (CGL),
thus preventing cysteine synthesis. Sulfasalazine (SAS) is a
pharmacological inhibitor of Sxc
- that prevents the import
of cystine from the transporter. Following treatment with
inhibitors of the transsulfuration pathway (PPG) or Sxc
-
(SAS), we measured intracellular GSH levels and GPX ac-
tivity in order to examine the importance of each pathway
in cellular redox regulation. Total cellular GSH was de-
creased by PPG treatment in all cell lines, and SAS did not
have any significant effect (Figure 3A). Transsulfuration
pathway inhibition with PPG resulted in decreased GPX
activity in all cell lines, and Sxc
- inhibition with SAS caused
decreased GPX activity in both non-induced and inducedoxic ovarian cancer cells. 2008, 2008-Ets1 and induced 2008-Ets1
x capacity was examined. A) Quantitative total GSH levels were signifi-
id not significantly affect GSH levels (n = 3). B) Like total GSH levels,
ade of the transsulfuration pathway. SAS treatment resulted in de-
rotein expression of factors involved in redox regulation was measured
as a loading control (n = 3).
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eral factors involved in redox state regulation was examined
via Western blot (Figure 3C). Ets-1 is very lowly expressed
in 2008 cells compared to 2008-Ets1 cells and their induced
counterparts. In addition, the protein levels of xCT, GPX-1,
and GPX-2 were increased with overexpression of Ets-1. In
2008 cells, both PPG and SAS treatments caused a de-
creased in hypoxia inducible factor 1α (HIF-1α) protein. In
contrast, PPG treatment resulted in the increase of both
GPX-1 and GPX-2 protein levels. In 2008-Ets1 cells, inhib-
ition of the transsulfuration pathway with PPG decreased
the protein expression of HIF-1α, xCT, and GPX-1, while
SAS decreased the expression of GPX-1. Induced 2008-
Ets1 cells showed decreases in HIF-1α, xCT, and GPX-2
protein following PPG treatment, and decreased GPX-2
after treatment with SAS.
Ets-1 recruits Sxc
- to maintain glutathione pool under
oxidative stress
Glucose oxidase treatment was used to induce oxidative





























































Figure 4 Ets-1 recruits Sxc
- to maintain glutathione pool under oxidat
cultures, and successfully increased intracellular ROS levels in all cell lines. B
intracellular GSH levels. The amount of GSH was decreased by SAS in onlylines (Figure 4A). Intracellular GSH levels were de-
creased in response to transsulfuration inhibition in all
cell types, but only Ets-1 overexpressing cells displayed
decreased GSH levels following inhibition of Sxc
-
(Figure 4B). The decrease in GSH levels following sulfa-
salazine treatment was inversely correlated with in-
creased Ets-1 expression.
Ets-1 redox regulation involves changes in HIF-1α and
GPX-2 protein levels
Following the induction of oxidative stress, the protein
expression of the redox-related proteins HIF-1α, xCT,
GPX-1, and GPX-2 were determined via Western blot
(Figure 5A). When comparing 2008, 2008-Ets1, and
induced 2008-Ets1 cells, the expression of HIF-1α is
decreased, while the expression of xCT and GPX-1
are increased in response to Ets-1 overexpression
(Figure 5B). In response to inhibitor treatment, PPG
decreased HIF-1α and GPX-2 expression in all cell lines,
in addition to increasing Ets-1 and GPX-1 protein levels
















ive stress. A) Glucose oxidase was used to induce oxidative stress in
) Under oxidative stress, PPG treatment resulted in decreased





Figure 5 Ets-1 redox regulation involves changes in HIF-1 and GPX-2 protein levels. A) The protein expression of redox balance-related
factors was examined by Western blot. B) Both xCT and GPX-1 protein are increased in correlation with Ets-1 overexpression, while HIF-1α and
GPX-2 showed a trend to decreased with higher levels of Ets-1. C) In 2008 cells, HIF-1α and GPX-2 were decreased in response to PPG treatment,
while GPX-1 was increased with both PPG and SAS. D) In 2008-Ets1 cells, decreased protein expression was observed for HIF-1α and GPX-2, while
SAS also decreased GPX-2 protein levels. E) Similarly, tetracycline-induced 2008-Ets1 cells displayed decreased protein expression of HIF-1α and
GPX-2 following PPG and SAS treatment.
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inhibition of Sxc
- decreased GPX-2 in both Ets-1-
expressing lines, and also decreased HIF-1α protein
levels in induced 2008-Ets1 cells (Figure 5C-D).
Discussion
In the present study, we have identified Ets-1 as a medi-
ator of glutathione antioxidant capacity in an ovarian
cancer model of Ets-1 overexpression, shown that Ets-1
recruits the membrane antiporter Sxc
- to increase intra-
cellular GSH levels, and described a potential mechan-
ism to overcome drug resistance in ovarian cancer cells.
The importance of Ets-1 in cancer has been investigated
extensively with regards extracellular matrix remodeling
and angiogenesis [19,20]. Our laboratory recently identi-
fied Ets-1 as a key regulator of cancer metabolism that
encourages glycolytic dependence and decreases oxida-
tive phosphorylation [10]. To our knowledge, the presentstudy is the first report to define a role for Ets-1 in redox
state regulation of intracellular glutathione levels in
cancer cells.
Cellular redox balance is an important regulator of
cancer cell proliferation, apoptotic evasion, and thera-
peutic resistance. Thus, Ets-1-mediated alterations in
glutathione antioxidant activity likely account, at least in
part, for the associations observed with overexpression
of this factor and poor prognosis, advanced malignancy,
and enhanced metastatic potential in several types of
cancer [21-30]. We have chosen to further characterize
the function of Ets-1 in ovarian cancer based on our
previous work using the 2008/C13* ovarian cancer
model of cisplatin resistance [8]. C13* cells are a variant
of 2008 adenocarcinoma cells that were generated
from 2008 cells subjected to 13 consecutive rounds of
cisplatin treatment. These cells display elevated mito-
chondrial membrane potential, enhanced DNA repair
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which all contribute to therapeutic resistance [8]. As
Ets-1 is prominently overexpressed in C13* cells, we
generated a stable overexpression model of Ets-1 in
2008 cells and have since characterized novel roles for
Ets-1 in ovarian cancer cells using this model [8,10,31].
In this study, we have shown that overexpression of Ets-
1 leads to decreased intracellular ROS levels, concomi-
tantly with increased intracellular GSH levels and GPX
activity. These findings are significant as they suggest a
mechanism for the increased tolerance to oxidative
stress observed in aggressive, drug-resistant ovarian
cancer cells (Figure 6).
GSH plays a key role in the antioxidant capabilities of
cancer cells, and high levels confer protection against
oxidative stress-inducing chemotherapy and ionizing ra-
diation. The development of targeted agents that deplete
GSH would improve the ability of these agents to induce
cancer cell death, as low levels of GSH trigger mitochon-
drial apoptosis, necrosis, and autophagy [14,15,32,33].
Depletion of GSH can be achieved through the inhib-
ition of GSH transport, enhancement of efflux from
cells, or by limiting cysteine availability causing impaired
GSH synthesis. We have reported here that the overex-
pression of Ets-1 induces increased expression and activ-
ity of Sxc
-, suggesting that GSH depletion by limiting
intracellular cysteine might be a viable therapy in these
cells. Treatment with SAS, an anti-inflammatory drug
that blocks Sxc
- transport, resulted in a significant de-
crease in GPX activity but not total GSH levels under
basal conditions. However, decreases in GSH levels and
GPX activity were achieved following treatment with
PPG, which blocks cysteine synthesis by the transsul-
furation pathway. Therefore, we suggest that under basal
conditions ovarian cancer cells rely predominantly on
the transsulfuration pathway to maintain GSH levels
irrespectively of Ets-1 expression level.
As many therapeutic agents function by inducing oxi-
dative stress, we also examined the effects of SAS and
PPG on ovarian cancer cells exposed to such conditions
by glucose oxidase treatment. Interestingly, we have
shown that GSH depletion following SAS treatment cor-
relates with Ets-1 overexpression levels, where cancer
cells that express high levels of Ets-1 display greatly de-
creased GSH levels following Sxc
- blockade. Protein ex-
pression of the Sxc
- catalytic subunit xCT and glutathione
peroxidase enzyme GPX-1 were increased in correlation
with increasing Ets-1 expression suggesting that they
may be target genes of Ets-1. Interestingly, the protein
expression of HIF-1α and GPX-2 were decreased con-
comitantly in response to transsulfuration pathway in-
hibition in all cell lines, an effect that was mimicked
with SAS treatment only in Ets-1 overexpression lines.
These findings not only suggest that HIF-1α and GPX-2are involved in the maintenance of intracellular GSH
levels, but also that cellular redox state can influence the
expression, and likely the stability of HIF-1α.
The master regulator of cellular redox state is arguably
the transcription factor nuclear factor (erythroid-
derived)-like-2 (Nrf2), which initiates the antioxidant
response pathway primarily responsible for cellular
defense against oxidative stress and is frequently mu-
tated in cancer [34]. Our laboratory has previously
established that Ets-1 is a target gene of Nrf2 via binding
of an antioxidant response element within the Ets-1 pro-
moter region [31]. However, a hypoxia response element
within the promoter region was also found to be in-
volved in the transcriptional induction of Ets-1 expres-
sion, suggesting an important role for HIF-1α. The
impact of redox balance fluctuation on HIF-1α expres-
sion and stability is well defined, thus we examined HIF-
1α protein expression in our ovarian cancer model fol-
lowing GSH depletion. Not surprisingly, the expression
of HIF-1α decreased in correlation with decreased ROS
levels in our 2008 cell model and following transsulfura-
tion pathway blockade. Under oxidative stress, HIF-1α
was decreased in response to SAS treatment only in cells
that overexpress Ets-1 suggesting that GSH depletion
regulates HIF-1α levels in ovarian cancer cells. In agree-
ment with our findings, the ability of redox state fluctua-
tions to affect HIF-1α expression was recently observed
in hepatocellular carcinoma cells following inhibition of
GSH synthesis by the chemotherapeutic agent buthio-
nine sulphoximine [35], as well as in astrocytes where
GSH depletion decreased HIF-1α expression [36]. Con-
sidering these results, further investigation into the
interrelationship between Ets-1, Nrf2, and HIF-1α in
ovarian cancer cells is warranted.
Our results suggest that agents that deplete GSH
levels may be effective sensitizing agents in aggres-
sive, drug-resistant ovarian cancers when used as a
pre-treatment prior to conventional oxidative stress-
inducing therapies. There is precedence for such a
therapeutic strategy, as SAS specifically has shown
therapeutic promise in pancreatic [18,37], lung
[38,39], hepatocellular [40], prostate [41], and breast
cancers [42]. These studies illustrated that SAS has
the ability to decrease tumour growth in vivo in
several types of cancer, and can also enhance the
efficacy of the chemotherapeutic agents etoposide
[37], gemcitabine [18,37], and doxorubicin [39,42].
Gemcitabine and cisplatin are commonly used in
combination together, and since Ets-1 is involved in
cisplatin resistance, further study of the validity of
pre-treatment of GSH-depleting agents with gemci-
tabine and cisplatin combination therapy for ovarian
cancer is warranted [8]. The diverse functional roles



























Figure 6 Proposed mechanism for Ets-1 mediated drug resistance in ovarian cancer. A) In the absence of abundant Ets-1 expression, the
transsulfuration pathway is the main cysteine source for glutathione synthesis. Treatment with chemotherapeutic agents induces oxidative stress
that causes DNA damage and GSH depletion by increasing intracellular ROS, leading to cell death. B) Under the control of Ets-1 expression,
Sxc
- activity is increased to bolster cysteine stores thereby increasing intracellular glutathione. High levels of glutathione prevent oxidative stress-
inducing therapies from causing an accumulation of ROS. Thus, Ets-1 overexpression may play an important role in the drug resistance often
observed in aggressive ovarian cancer.
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therapeutic target, although the limitations to such
an approach are significant. Several other Ets factors
share sequence homology with Ets-1, and thus dir-
ect inhibition of Ets-1 specifically is unreasonable.Therefore, further examination of the regulation of
Ets-1 and the functional consequences of its overex-
pression are of particular interest to the develop-
ment of novel therapeutic approaches for ovarian
cancer.
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Ovarian cancer cells that overexpress Ets-1 display a
more active glutathione antioxidant system, a character-
istic that could account for the chemotherapeutic
resistance previously observed in these cells [8]. Under
conditions of oxidative stress, Ets-1 recruits the Sxc
-
transporter to bolster cellular glutathione levels resulting
in decreased ROS levels, increased intracellular GSH,
and increased GPX activity. In blocking the activity of
Sxc
-, GSH levels are depleted and cell viability is compro-
mised, suggesting that this approach may reduce resist-
ance to oxidative stress-inducing therapies. Although we
have focused on an ovarian cancer cell model for this
study, the potential applicability of these findings is
broad because Ets-1 overexpression is frequently associ-
ated with a wide spectrum of aggressive, advanced
cancers.
Methods
Cell culture and treatments
The human ovarian carcinoma cell line 2008 was kindly
provided by Dr. Paul Andrews (Georgetown University,
Rockville, MD, United States) [43], and were maintained
in RPMI 1640 medium supplemented with 10% fetal bo-
vine serum and 2% penicillin/streptomycin. Stable cell
line 2008-Ets1 was maintained in growth medium as
described with the addition of 200 ng/ml selective
antibiotic (zeocin). All cells were kept at 37°C in a
humidified atmosphere of 5% CO2. All the experiments
performed with these cell lines were approved by the
Presidential Biosafety Advisory Committee of McMaster
University, Canada. Media and supplements were
purchased from Invitrogen Life Technologies (ONT,
Canada). When cells reached 40-50% confluency, the
cultures were exposed to either PPG or SAS at 2.5 mM
and 50 uM respectively for 24 hours prior to isolation or
analysis. To induce oxidative stress in cultures, cells
were treated with 10 mU/mL glucose oxidase and/or
PPG/SAS for 24 hours prior to isolation or analysis.
Western Blotting and densitometry analysis
Whole cell lysates were collected, and 30 μg of protein
was separated by 10% SDS-PAGE electrophoresis, trans-
ferred to PVDF membrane, and blocked for 1 hr in 5%
skim milk TBS-T. Membranes were incubated overnight
with antibody reactive to Ets-1 (Abcam, MA, United
States), HIF-1α (Cell Signaling, MA, United States), xCT
(Abcam), GPX1 (Abcam), GPX2 (Abcam), or Actin (Cell
Signaling) in 0.5% TBS-T. Following primary antibody
incubation, membranes were washed and incubated
for 2 hrs with horseradish peroxidase-linked anti-mouse
or anti-rabbit IgG secondary antibody as appropriate
(Cell Signaling). Proteins were detected by ECL chemilu-
minescence reagent (Amersham, NJ, United States), andexposed to film. Densitometry analysis was performed
using ImageJ software available at http://rsb.info.nih.gov/ij
and developed by Wayne Rasband, National Institutes of
Health, Bethesda, MD, USA.
Glutamate release and cell viability assays
Glutamate levels in the culture medium were evaluated
using the AMPLEX redW glutamic acid assay kit, which
was optimized for higher glutamate concentrations by
the omission of L-alanine and L-glutamate pyruvate
transaminase from the reaction [44]. Cell viability was
measured using Crystal Violet staining with all cell lines
seeded at 10,000 cells per well, and normalized to a
standard curve of cell numbers.
Intracellular ROS assay
Intracellular ROS levels were measured using CM2-
H2DCFDA reagent (Invitrogen), which is cleaved once
inside the cell allowing the DCF dye to bind to ROS spe-
cies resulting in fluorescence. Cells were plated in 96-
well plates and grown to 70-90% confluency in phenol
red-free medium. CM2-H2DCFDA reagent was reconsti-
tuted in DMSO, and 10 μM was added to each experi-
mental well using phenol red-free medium containing
10% FBS. Following a 30 min incubation to allow the
dye to load into cells, plates were washed twice with
PBS, and allowed to recover in phenol red-free medium
for 10 minutes. Plates were then treated with 250 μM
H2O2 and read in a Cytofluor fluorescent plate reader at
485 nm excitation and 530 nm emission for 1 hour.
Plates were then stained with Crystal Violet, dried over-
night, solubilized with SDS, and read at 570 nm.
Arbitrary fluorescent values were normalized to Crystal
Violet absorbance values, and reported as Arbitrary
Fluorescent Units (AFU).
Determination of intracellular GSH concentration
Metabolite cell extracts were prepared as described by
Rahman et al. [45]. Briefly, cultures were grown to
70-80% confluency, washed with PBS, and pelleted twice.
Extracts were resuspended in cold extraction buffer con-
taining 0.06% sulfosalicylic acid, homogenized using a
26.5 gauge needle, lyzed via freeze/thaw at −70°C, pel-
leted, and the supernatant was retained as used for GSH
measurement. Intracellular GSH content of the metabol-
ite extracts was measured as described [45]. The concen-
tration of total GSH was normalized to the protein
concentration of each extract.
GPX activity assay
Glutathione peroxidase enzyme activity was measured
using the glutathione peroxidase activity kit from Enzo
Life Sciences (NY, USA) according to the manufacturer
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protein concentration of the each cell extract.
Statistical analysis
Data is presented as the mean +/− standard deviation
from at least three independent experiments. Statistically
significant differences between sample groups were deter-
mined using a Student’s t-test or ANOVA where applic-
able, with a p-value ≤ 0.05 considered to be statistically
significant (p ≤ 0.05 = *, p ≤ 0.01 = **, p ≤ 0.001 = ***).
Abbreviations
AFU: Arbitrary fluorescent units; CGL: Cystathionine γ-lyase enzyme; Ets-1:
V-ets erythroblastosis virus E26 oncogene homolog 1; GPX: Glutathione
peroxidase; GSH: Reduced glutathione; HIF-1α: Hypoxia inducible factor 1α;
Nrf2: Nuclear factor (erythroid-derived)-like-2; PPG: Propargylglycine;
ROS: Reactive oxygen species; SAS: Sulfasalazine; Sxc
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